Please use this identifier to cite or link to this item:
DC FieldValueLanguage
dc.contributor.authorFarhat, Fadien_US
dc.contributor.authorHussein, Marwaen_US
dc.contributor.authorSbaity, Emanen_US
dc.contributor.authorAlsharm, Abdullahen_US
dc.contributor.authorRasul, Kakilen_US
dc.contributor.authorKhairallah, Saaden_US
dc.contributor.authorAssi, Tareken_US
dc.contributor.authorAllahverdi, Niloofaren_US
dc.contributor.authorOthman, Ahmaden_US
dc.contributor.authorKattan, Josephen_US
dc.description.abstractObjectives This study described the epidemiological, clinical, and survival profiles of patients with gastrointestinal stromal tumor (GIST) in North Africa and the Middle East (AfME). Methods This regional, multicenter, observational, retrospective study collected 11-year data on demographics, medical history, disease characteristics, current treatment approaches of GIST, the safety of the most common tyrosine kinase inhibitors (TKIs), second cancers, and survival status. Results Data of 201 eligible patients were analyzed: mean age was 56.9 ± 12.6 years; 111 (55.2%) patients were men, 21 (10.4%) patients had previous personal malignancy. The most common clinical presentation of GIST was dysphagia [92 (45.8%) patients]. The stomach was the most common primary site in 120 (60.7%) patients, 171 (85.1%) patients had localized disease at diagnosis. 198 (98.5%) GIST cases were CD117/CD34-positive. Imatinib was used in the neoadjuvant (18/21 patients), adjuvant (85/89 patients), and first-line metastatic treatment (28/33 patients) settings. The most common non-hematological toxicity associated with TKIs was vomiting in 32/85 (37.6%) patients. Overall, 100 (49.8%) patients (95%CI: 42.8–56.7%) were alive and disease-free while 30 (14.9%) patients were alive with active disease. Conclusion Presentation of GIST in our AfME population is consistent with global reports, being more frequent in patients >50 years old and having the stomach as the most common primary site. Unlike what is usually reported, though, we did have more patients with lymphatic spread of the disease. Despite the global trend and advances in the treatment of GIST according to molecular profile, this is still far to happen in our population given the lack of access to molecular profiles and the high associated cost.en_US
dc.publisherNational Library of Medicineen_US
dc.subjectGastrointestinal stromal tumor (GIST)en_US
dc.subjectMutational analysesen_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.titleGastrointestinal stromal tumor in North Africa and the middle east: updates in presentation and management from an 11-year retrospective cohorten_US
dc.typeJournal Articleen_US
dc.contributor.affiliationFaculty of Medicineen_US
dc.description.statusIn Pressen_US
dc.relation.ispartoftextHospital Practiceen_US
Appears in Collections:Faculty of Medicine
Show simple item record

Record view(s)

checked on Jul 13, 2024

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.